In support of the reignited Cancer Moonshot’s goal of fostering data sharing in cancer research, the National Cancer Institute has launched the Molecular Characterization Initiative for pediatric tumors (The Cancer Letter, Feb. 4, 2022).
MD Anderson Cancer Center showed that first-line treatment with axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 CAR T-cell therapy, achieved a high rate of complete response in patients with high-risk large B-cell lymphoma.
A computational approach developed by researchers at MD Anderson Cancer Center combines data from parallel gene-expression profiling methods to create spatial maps of a given tissue at single-cell resolution. The resulting maps can provide insights into the cancer microenvironment and other tissue types.
An outreach program at The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) is mailing free at-home colon cancer screening tests to Black primary care patients who have not yet had their routine colonoscopy.
A UPMC-led study suggests that healthcare professionals exposed to SARS-CoV-2 can safely return to work after seven days of quarantine if they are asymptomatic and receive a negative COVID-19 test. The findings, from the first reported study evaluating reduced quarantine duration in a healthcare setting, offer a potential new strategy for mitigating staffing shortages prior to a next wave of COVID-19 cases.
FDA approved Opdualag (nivolumab and relatlimab-rmbw) for adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma. Opdualag is a fixed-dose combination of the LAG-3-blocking antibody relatlimab and the programmed death receptor-1 blocking antibody nivolumab.
FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibition and taxane-based chemotherapy.
PathAI and Cleveland Clinic announced a five-year strategic collaboration leveraging PathAI’s quantitative pathology algorithms to conduct translational research and to use as clinical diagnostics in multiple disease areas.
Andrew Chapman was named director of the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and executive vice president of oncology services, effective March 15. Chapman has been serving as the center’s interim director for the past year.
Fight Colorectal Cancer hosted an advocacy event on the National Mall March 16, “Call-on Congress,” to discuss ways to reduce colorectal cancer incidence, improve treatment, and mitigate health disparities. The event included a flag installation on the Mall to honor those affected by CRC.
